Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 27

1.

Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer.

Bertenshaw GP, Yip P, Seshaiah P, Zhao J, Chen TH, Wiggins WS, Mapes JP, Mansfield BC.

Cancer Epidemiol Biomarkers Prev. 2008 Oct;17(10):2872-81. doi: 10.1158/1055-9965.EPI-08-0464.

2.

Combining a symptoms index with CA 125 to improve detection of ovarian cancer.

Andersen MR, Goff BA, Lowe KA, Scholler N, Bergan L, Dresher CW, Paley P, Urban N.

Cancer. 2008 Aug 1;113(3):484-9. doi: 10.1002/cncr.23577.

3.

Systematic evaluation of candidate blood markers for detecting ovarian cancer.

Palmer C, Duan X, Hawley S, Scholler N, Thorpe JD, Sahota RA, Wong MQ, Wray A, Bergan LA, Drescher CW, McIntosh MW, Brown PO, Nelson BH, Urban N.

PLoS One. 2008 Jul 9;3(7):e2633. doi: 10.1371/journal.pone.0002633.

4.

A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group study.

Greene MH, Piedmonte M, Alberts D, Gail M, Hensley M, Miner Z, Mai PL, Loud J, Rodriguez G, Basil J, Boggess J, Schwartz PE, Kelley JL, Wakeley KE, Minasian L, Skates S.

Cancer Epidemiol Biomarkers Prev. 2008 Mar;17(3):594-604. doi: 10.1158/1055-9965.EPI-07-2703.

5.

Diagnostic markers for early detection of ovarian cancer.

Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, Tenthorey J, Leiser A, Flores-Saaib R, Yu H, Azori M, Rutherford T, Schwartz PE, Mor G.

Clin Cancer Res. 2008 Feb 15;14(4):1065-72. doi: 10.1158/1078-0432.CCR-07-1569. Epub 2008 Feb 7. Erratum in: Clin Cancer Res. 2008 Aug 15;14(16):5308. Clin Cancer Res. 2008 Nov 1;14(21):7158.

6.

The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass.

Moore RG, Brown AK, Miller MC, Skates S, Allard WJ, Verch T, Steinhoff M, Messerlian G, DiSilvestro P, Granai CO, Bast RC Jr.

Gynecol Oncol. 2008 Feb;108(2):402-8. Epub 2007 Dec 3.

PMID:
18061248
7.

Discrimination between benign and malignant adnexal masses by specialist ultrasound examination versus serum CA-125.

Van Calster B, Timmerman D, Bourne T, Testa AC, Van Holsbeke C, Domali E, Jurkovic D, Neven P, Van Huffel S, Valentin L.

J Natl Cancer Inst. 2007 Nov 21;99(22):1706-14. Epub 2007 Nov 13.

PMID:
18000221
8.

Management of adnexal mass.

Myers ER, Bastian LA, Havrilesky LJ, Kulasingam SL, Terplan MS, Cline KE, Gray RN, McCrory DC.

Evid Rep Technol Assess (Full Rep). 2006 Feb;(130):1-145. Review.

9.

Predictors of comprehensive surgical treatment in patients with ovarian cancer.

Goff BA, Matthews BJ, Larson EH, Andrilla CH, Wynn M, Lishner DM, Baldwin LM.

Cancer. 2007 May 15;109(10):2031-42.

10.

C-reactive protein concentrations and subsequent ovarian cancer risk.

McSorley MA, Alberg AJ, Allen DS, Allen NE, Brinton LA, Dorgan JF, Pollak M, Tao Y, Helzlsouer KJ.

Obstet Gynecol. 2007 Apr;109(4):933-41.

PMID:
17400857
11.

Role of cancer antigen-125 from pleural & ascitic fluid samples in non malignant conditions.

Kalantri Y, Naik G, Joshi SP, Jain A, Phatak S, Chavan R, Hemvani N, Chitnis DS.

Indian J Med Res. 2007 Jan;125(1):25-30.

PMID:
17332654
12.

Development of an ovarian cancer symptom index: possibilities for earlier detection.

Goff BA, Mandel LS, Drescher CW, Urban N, Gough S, Schurman KM, Patras J, Mahony BS, Andersen MR.

Cancer. 2007 Jan 15;109(2):221-7.

13.

Surveillance of women at high risk for hereditary ovarian cancer is inefficient.

Oei AL, Massuger LF, Bulten J, Ligtenberg MJ, Hoogerbrugge N, de Hullu JA.

Br J Cancer. 2006 Mar 27;94(6):814-9.

14.

Logistic regression model to distinguish between the benign and malignant adnexal mass before surgery: a multicenter study by the International Ovarian Tumor Analysis Group.

Timmerman D, Testa AC, Bourne T, Ferrazzi E, Ameye L, Konstantinovic ML, Van Calster B, Collins WP, Vergote I, Van Huffel S, Valentin L; International Ovarian Tumor Analysis Group..

J Clin Oncol. 2005 Dec 1;23(34):8794-801.

PMID:
16314639
15.

Multiplexed immunobead-based cytokine profiling for early detection of ovarian cancer.

Gorelik E, Landsittel DP, Marrangoni AM, Modugno F, Velikokhatnaya L, Winans MT, Bigbee WL, Herberman RB, Lokshin AE.

Cancer Epidemiol Biomarkers Prev. 2005 Apr;14(4):981-7.

16.

Validation of referral guidelines for women with pelvic masses.

Im SS, Gordon AN, Buttin BM, Leath CA 3rd, Gostout BS, Shah C, Hatch KD, Wang J, Berman ML.

Obstet Gynecol. 2005 Jan;105(1):35-41.

PMID:
15625139
17.

Preoperative sensitivity and specificity for early-stage ovarian cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-stimulating factor using mixtures of multivariate normal distributions.

Skates SJ, Horick N, Yu Y, Xu FJ, Berchuck A, Havrilesky LJ, de Bruijn HW, van der Zee AG, Woolas RP, Jacobs IJ, Zhang Z, Bast RC Jr.

J Clin Oncol. 2004 Oct 15;22(20):4059-66. Epub 2004 Sep 20.

PMID:
15381683
18.

Calculation of the risk of ovarian cancer from serial CA-125 values for preclinical detection in postmenopausal women.

Skates SJ, Menon U, MacDonald N, Rosenthal AN, Oram DH, Knapp RC, Jacobs IJ.

J Clin Oncol. 2003 May 15;21(10 Suppl):206s-210s.

PMID:
12743136
19.

Cancer antigen 125 associated with multiple benign and malignant pathologies.

Miralles C, Orea M, España P, Provencio M, Sánchez A, Cantos B, Cubedo R, Carcereny E, Bonilla F, Gea T.

Ann Surg Oncol. 2003 Mar;10(2):150-4.

PMID:
12620910
20.

Use of proteomic patterns in serum to identify ovarian cancer.

Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA.

Lancet. 2002 Feb 16;359(9306):572-7.

PMID:
11867112

Supplemental Content

Support Center